Evidence map›Paper›PMID 27313723›Full record

ArticleOncology letters2016

Significance of ETV6 rearrangement in acute promyelocytic leukemia with t(15;17)/promyelocytic leukemia/retinoic acid receptor alpha.

N A Gao, Wen-Zheng Yu, Xue-Xia Wang, Jian-Rong Sun, Ning Yu, Zeng-Yan Liu, Xiao-Dan Liu, Ren-Tong Liu, Rui Feng, Bu-Tong Ding and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

N A GaoDepartment of Hematology, Central Hospital of Jinan, Shandong University School of Medicine, Jinan, Shandong 250013, P.R. China; Department of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Wen-Zheng YuDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Xue-Xia WangDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Jian-Rong SunDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Ning YuDepartment of Pathology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Zeng-Yan LiuDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Xiao-Dan LiuDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Ren-Tong LiuDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Rui FengDepartment of Hematology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China.
Bu-Tong DingDepartment of Hematology, Central Hospital of Jinan, Shandong University School of Medicine, Jinan, Shandong 250013, P.R. China.
Tan SangDepartment of Hematology, Central Hospital of Jinan, Shandong University School of Medicine, Jinan, Shandong 250013, P.R. China.
Nong-Jian GuoDepartment of Hematology, Central Hospital of Jinan, Shandong University School of Medicine, Jinan, Shandong 250013, P.R. China.
Binzhou University · CNShandong University · CNBinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is a common subtype of acute myeloid leukemia in China. Since the application of arsenic trioxide and all-trans retinoic acid in the treatment of APL, the prognosis has greatly improved. However, ~20% of patients with APL relapse upon completing chemotherapy. Decreasing the relapse rate and incidence of early mortality may pose the greatest challenges for the future management of APL. Recently, Ets variant 6 (ETV6) was reported to be involved in a variety of translocations associated with hematological malignancies of myeloid and lymphoid origin. To date, little is known about the clinical implication of ETV6 rearrangement in APL. In the present study, ETV6 rearrangement was examined by split-signal fluorescence

Indexed as

acute promyelocytic leukemiaEts variant 6 geneprognosisrearrangementsplit-signal FISH

Identifiers

PMID27313723
PMCPMC4888070
OpenAlexW2345787434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.